Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-α production by human monocytes

18Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that suppresses the production of tumour necrosis factor-α (TNF-α) by monocytes and macrophages. Suppressor of cytokine signalling-3 (SOCS3), a negative regulator of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, is induced following IL-10 exposure but recent studies in mice suggest that SOCS3 only targets gp-130-dependent signal transduction pathways. Understanding the signalling pathways responsible for IL-10-mediated effects in primary human monocytes is relevant to human inflammatory disease and necessary for the identification of potential therapeutic targets. An adenoviral transfection system was used to express different levels of SOCS3 (quantified experimentally with its tag green fluorescent protein (GFP)) with the aim of investigating the role of SOCS3 in LPS-induced and IL-10-mediated suppression of TNF-α production by non-transformed human monocytes. SOCS3 over-expression had no effect on TNF-α mRNA levels induced by LPS or LPS plus IL-10, or on IL-10 phosphorylation of STAT3, STAT1 and ERK1/2. When data from all donors were combined, adenoviral overexpression of SOCS3 significantly reversed the suppressive effects of IL-10 on LPS-induced TNF-α production after 2 hr. However, there was a direct correlation between mean GFP intensity (extent of viral infection) and extent of reversal of IL-10's inhibitory effects. Physiological levels of SOCS3 detected in IL-10-exposed human monocytes had no effect on LPS-induced TNF-α production. Although overexpression of SOCS3 to supraphysiological levels transiently antagonized the regulatory properties of IL-10 by a post-transcriptional mechanism, these findings suggest that under pathological conditions SOCS3 does not control LPS-activation or the anti-inflammatory properties of IL-10 in primary human monocytes. © 2006 Blackwell Publishing Ltd.

References Powered by Scopus

Interleukin-10-deficient mice develop chronic enterocolitis

3852Citations
N/AReaders
Get full text

Two types of mouse t helper cell: IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones

2681Citations
N/AReaders
Get full text

Interleukin-10 therapy - Review of a new approach

832Citations
N/AReaders
Get full text

Cited by Powered by Scopus

SOCS proteins, cytokine signalling and immune regulation

1313Citations
N/AReaders
Get full text

LPS-induced cytokine production in human monocytes and macrophages

519Citations
N/AReaders
Get full text

Putting out the fire: Coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins

148Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Prêle, C. M., Keith-Magee, A. L., Yerkovich, S. T., Murcha, M., & Hart, P. H. (2006). Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-α production by human monocytes. Immunology, 119(1), 8–17. https://doi.org/10.1111/j.1365-2567.2006.02383.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

42%

Researcher 4

33%

Professor / Associate Prof. 2

17%

Lecturer / Post doc 1

8%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 7

54%

Biochemistry, Genetics and Molecular Bi... 3

23%

Immunology and Microbiology 2

15%

Engineering 1

8%

Save time finding and organizing research with Mendeley

Sign up for free